We recorded differences between treatment groups in simeprevir or telaprevir-related adverse events ( 69 % [ 261/379 ] in the simeprevir group vs 86 % [ 330/384 ] in the telaprevir group ) , serious adverse events ( 2 % [ 8/379 ] vs 9 % [ 33/384 ] ) , and adverse events leading to simeprevir or telaprevir discontinuation ( 2 % [ 7/379 ] vs 8 % [ 32/384 ] ) .